If after many robust trials, you became aware that you were...

If after many robust trials, you became aware that you were sitting on a treatment for cancer that not only beat SOC in efficacy, but cost, ease of use, adverse events.

Would you sell it for $5-$7b? or would you either look for a better offer or take it all the way to production.

I honestly believe that the data sells itself.

If we have what we believe we do with Vaxinia then you're grossly undervaluing our IP.

We talk like we're desperate for cash now. But in reality it's only certain SH that are individually desperate. I don't think mgmt are.

You guys can sell out early for $0.75-$1.5. Then kick yourselves for the rest of your life for being trigger happy.

I'm here for the long haul.